DRIXORAL PLUS
LOE Approachingacetaminophen; dexbrompheniramine maleate; pseudoephedrine sulfate
NDAORALTABLET, EXTENDED RELEASE
Approved
May 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DRIXORAL PLUS (acetaminophen; dexbrompheniramine maleate; pseudoephedrine sulfate) by Merck & Co.. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 1987.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Drixoral Plus is a fixed-dose combination tablet containing acetaminophen (analgesic/antipyretic), dexbrompheniramine maleate (antihistamine), and pseudoephedrine sulfate (decongestant) in extended-release formulation. It is indicated for temporary relief of minor aches, pains, headache, sore throat, flu symptoms, toothache, and fever associated with the common cold. The mechanism combines central analgesic/antipyretic activity with peripheral decongestant and antihistamine effects.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100); expect significant team restructuring and transition planning to generic/OTC market strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on DRIXORAL PLUS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.